19th Expert Committee on the Selection and Use of Essential Medicines
April 8-12; 2013
Expert peer review on application for “Ophthalmological preparation: Addition of Latanoprost”

1. Assessment of efficacy
   a. Have all relevant studies on efficacy been included
      yes
   b. Summarize the data on efficacy, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences)
      Latanoprost is slightly more effective compared to Timolol (current medicine on the List).
   c. Please provide any additional relevant information with reference

2. Assessment of safety
   a. Have all relevant studies on safety been included
      Yes
   b. Summarize the data on safety, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences)
      Reported ADR with Latanoprost is lower than those reported for Timolol.
   c. Please provide any additional relevant information with reference

3. Assessment of cost and availability
   a. Have all relevant data on cost and availability provided
      No
   b. Summarize the data on cost and cost effectiveness, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences)
      There is no comparative cost effectiveness study between Latanoprost and Timolol.
   c. Please provide any additional relevant information with reference
   d. Is the product available in several low and middle income countries?
      Yes.

4. Assessment of public health need
   b. Do guidelines (especially WHO guidelines) recommend this product?
      Latanoprost is not included in any WHO guideline.
5. Are there special requirements for use or training needed for safe/effective use?
   No.

6. Is the proposed product registered by a stringent regulatory authority?
   Yes

7. Any other comments
   This application is part of six applications submitted by the International Council of Ophthalmology for updating the Ophthalmological Preparations section of the EML. The applications are as following:
   1. Addition of Bevacizumab
   2. Addition of Ketorolac
   3. Addition of Latanoprost
   4. Addition of Ofloxacin
   5. Addition of Azithromycin
   6. Addition of Ketotifen

8. What is your recommendation to the committee (please provide the rationale)
   1. Current medicine on the list (Timolol) is comparatively effective and safe.
   2. Final recommendation: As second option for management of glaucoma “Add Latanoprost eye drop (50 mcg/ml) as a Complementary medicines to the ophthalmological preparations section”.